Heska is the ultimate parlay on the founder Robert Grieve.
This self serving slug has stacked the deck against anyone
who has ever belived in him over the years. Shareholders
have literally been reamed by Dr Grevious.
What is different now? Same screw, different day.
The reality is that this small and getting smaller microcap
doesn't have many last hoorah's. Grieve has no faithfull left
in his grand deception since the founding of Heska in 1997.
He is now at the twilight of his own timeline and he is looking for
the vested payday of buying insider options at a fraction of we
the faithfiul pay to participate.
Rest assured. The greedy always line their nest. Heska will not
be viable 5 yrs from now. The reality is in the actions, not
the verbage. COO Wilson has started exerting control over HSKA
and his track record is to sell, and move on. I'll be here
5 years from now. Will Heska? Not likely!
So what to discern from a guy who has chewed Heska hienie
for the last 5 yrs? Right now HSKA is a "Strong Buy" IMO.
Not by merit. Not by righteousness. Heska will beat numbers
in 2014 simply by virtue that they did so pitifully in 2013 comps.
In other words. Heska will do better in 2014 because of the
new COO Wilson who has an ever increasing vested interest
in this underperforming company.
Gotta agree: I like the also rans and under achievers.
I am out of NAVR , when they changed their headquarters
and symbol I took profits and said goodbye.
I have had a love/ hate relationship with HSKA over the
years. As you know. I dislike the mgmt but prefer to deal
with the devil I know; so I am temporarily long with a target
of 12.00. Heska has been a sell in May and go away stock
for the last 5 years.
The other company I like is SRT Startek. It has 32% insider
ownership and should be trading at a multiple of its peers.
My target is 40-50% higher.
I also like the unloved Gold and silver mining cos. I like SAND
which keeps ploughing new lows, as well as NEM, and SLW.
I agree. There are many new diagnostic analyzers being
introduced. What makes Abaxis different is their entire
platform which includes support, and knowledge of the
marketplace in veterinary sector. For a new contender to
displace an Idexx, Abaxis, or Heska, they would need sell
to prospects on more than price alone.
Abaxis future growth will not come from the veterinary
sector, but from partnership with Abbott in the sale and
placement of the piccollo analyzer. I expect to see
announcements coming in 2014 that will spur the growth
in Abaxis' human POC diagnostics.
Agree, Startek seems to be doing the right things to grow
business. But until the company starts showing consistent
quarter over quarter results, we are in a holding pattern.
2013 showed the beginnings of a turnaround for this
undervalued company. 2014 should confirm it.
If you're short, you need to worry that some of us
love em ugly. Don't get too greedy! There is no such
thing as "go forever" friend.
Heska announced a new addition to
its BOD's. Dr David Sveen joins Heska
having spent 13yrs in senior mgmt with
an investment banking firm. He also shared
time with Kevin Wilson, on the board of
Sound Technologies (The radiological imaging
company Wilson founded before Cuattro)
It would seem Wilson is exerting more control
over the future of Heska.
If Wilson can continue to grow sales as he did
in the last quarter, shareholders can hope
the management changes improve the
culture at Heska.
The whole sector is down due to the
mistaken perception that REITs will
suffer in a rising interest rate environment.
REITs are "not" all created the same.
Debt REIT's are susceptible to rising interest
rates because when rates go up, the rates
decrease the mark to market value of the debt.
VTR is not a debt REIT. VTR is an asset REIT.
In an improving economy the values of Ventas
properties will increase with inflation.
Rising interest rates will increase the borrowing
cost of VTR, but in an improving economy rents
and occupancy rates will more than offset the
debt service costs.
Happy turkey day to you doc.
I am holding steady with the TRIBute.
I may even bend an elbow to it with a liquid tribute.
One year ago on Dec 13th VTR was trading at $62+
and went ex-div'd paying .62 per share.
Ventas has increased its dividend to .67/share in
2013, and in less than 2 weeks goes ex-div'd.
VTR is a growth company, with a growth demographic
fueled by an aging population. It is now priced as a
value stock. To be able to buy VTR at a discount is a bargain.
dr....I agree completely. Let me also add
Bloomberg's announcement this week.
Highest demand employment is in Home
healthcare nursing with a 70% projected
increase over the next 10yrs.
Ventas will be a beneficiary of Obamacare
because it concentrates on private pay,
rather than reimbursement by insurance
companies. The haves will pay for their own
cares rather than stand at the end of the line
waiting on gov't to dictate their healthcare.
Private pay is where the money is in healthcare.
Ventas has high operating margins because
it has pricing power. Venta is a gift that will
keep on giving.
The seeking alpha recommendation, as well
as the Zacks Strong Buy rating, has given HSKA
One thing to note. Heska has been here before
several times over the last 5 years, and has
sputtered and failed.
While I am somewhat optimistic in the next
two quarters. I can't help stating the poor mgmt.
of this company hasn't changed.
Its been a rocky year for the Abaxis faithful.
It would be nice for mgmt. to share good news.
Perhaps another christmas div'd?
The company needs to put idle money to work.
Hoarding cash is a no guts, no return, strategy.
Five years of incubating cash has shown Abaxis
doesn't have much imagination.
The Form 4 stock options reveal more about
a company than appears on surface.
Heska sp jumped today on the award of
share options exercizeable at $7.36 share.
Who got the lion share of options?
CEO Dr Grieveious ( #1 weasel) 26.2M shares
COO newcomer Wilson with........25M shares
CFO numberbender Napolitano 20M shares
Mystery guy Steven Eyl ...................17M shares?
VP Asakhowicz.................................10M shares
VP Lippincott.....................................10M shares
Interesting by omission.........McGimley
Interesting by percentage.....Eyl
My take? There is internal rearrangement of the
principals, and the so called merger/buyout of
Cuattro was more of a capitulation by the Heska
CEO Grieve then he admitted in public.
It seems Steven Eyl and Wilson are, making the
substanitive moves and are the future hope of HSKA.
This is no longer Grieve's company on the long or
the short side. He is inconsequential and looking
for the golden parachute.
Although I agree with your Jim Cramer rant.
I disagree with your assessment of Ventas.
This is a perfect time to accumulate VTR,
and continue to average down if it goes
south to $52 as you predict.
VTR is the best of breed in healthcare
REIT's and has many catalysts for growth in
2014 beyond the aging demographics.
When large shareholders choose to
liquidate, there is not many times when
the opportunity presents without dramatically
effecting a low volume illiquid stock.
Heskas positive earnings report gave the
opportunity last week and long time stakeholder
Gamco chose to sell which pressure the sp.
Gamco sold 60,435 shares. I suspect the other
culprit was Zesiger.
If sellers are done liquidating. The downward
pressure on HSKA is lessened.
Every quarter is a kaa-ching for Abaxis.
Throughout the financial crisis, if I had
one complaint. ABAX sits on a pile of cash
that gives no return. Last year ABAX issued
a one time dividend in December, rewarding
the faithful. IMO Abaxis needs to put some of
this cash to work in order to sustain growth.
How about an acquisition, or another alliance
with a company that has a veterinary product
Abaxis can cross-sell across the existing
customer base? Its called value added Curt.
Heska has added an imaging dept. Idexx
already has imaging in its offerings.
Perhaps radiological imaging would be a
good thing for ABAX to look into.
Zesiger Capital drain this lizard all the
way down to a 52wk low of 5.16 as it
liquidated shares this year. Zesiger is
now listed in Yahoo stats as a 3% owner
of 176,287 shares. The doornob at Zesiger
has to be completely disgusted to sell into
low volume just before Heska reports the
first psitive earnings in over a year.
I suspect Zesiger is in the process of tax loss
sellin and completely liquidating its remaining
position out of complete disgust with Heska.
The volume spike of the past week has given
sellers a chance to get out.
For those smart enough to take advantage of this
dip in share price, it could be an opportunity
rewarded into year end, and beyond.
CEO Grieve and CFO Napolitano expressed
optimism in the last cc. It was, in fact, the
first glimmer of optimism from management
in the past year of no guidance, and hedged
It is my opinion that this CEO's words ring
hollow with a history of excuses, and under
performance. Until these sluggos put their
own money to work buying Heska? Why should
anyone else believe?